1-10 of 10
David P. Steensma
Close
Sort by
Journal Articles

Effects of IL-1β inhibition on anemia and clonal hematopoiesis in the randomized CANTOS trial

Janghee Woo, Darlene Lu, Andrew Lewandowski, Huilei Xu, Pablo Serrano, Margaret Healey, Denise P. Yates, Michael T. Beste, Peter Libby, Paul M. Ridker, David P. Steensma
Journal: Blood Advances
Blood Adv (2023) 7 (24): 7471–7484.
https://doi.org/10.1182/bloodadvances.2023011578
Published: 2023
Includes: Supplemental data
Journal Articles

An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS

Clinical Trials & Observations
Maximilian Stahl, Omar Abdel-Wahab, Andrew H. Wei, Michael R. Savona, Mina L. Xu, Zhuoer Xie, Justin Taylor, Daniel Starczynowski, Guillermo F. Sanz, David A. Sallman, Valeria Santini, Gail J. Roboz, Mrinal M. Patnaik, Eric Padron, Olatoyosi Odenike, Aziz Nazha, Stephen D. Nimer, Ravindra Majeti, Richard F. Little, Steven Gore, Alan F. List, Vijay Kutchroo, Rami S. Komrokji, Tae Kon Kim, Nina Kim, Christopher S. Hourigan, Robert P. Hasserjian, Stephanie Halene, Elizabeth A. Griffiths, Peter L. Greenberg, Maria Figueroa, Pierre Fenaux, Fabio Efficace, Amy E. DeZern, Matteo G. Della Porta, Naval G. Daver, Jane E. Churpek, Hetty E. Carraway, Andrew M. Brunner, Uma Borate, John M. Bennett, Rafael Bejar, Jacqueline Boultwood, Sanam Loghavi, Jan Philipp Bewersdorf, Uwe Platzbecker, David P. Steensma, Mikkael A. Sekeres, Rena J. Buckstein, Amer M. Zeidan
Journal: Blood Advances
Blood Adv (2023) 7 (12): 2709–2714.
https://doi.org/10.1182/bloodadvances.2022008747
Published: 2023
Journal Articles

Historical expectations with DNA methyltransferase inhibitor monotherapy in MDS: when is combination therapy truly “promising”?

Clinical Trials & Observations
Andrew M. Brunner, Geoffrey Fell, David P. Steensma
Journal: Blood Advances
Blood Adv (2022) 6 (9): 2854–2866.
https://doi.org/10.1182/bloodadvances.2021006357
Published: 2022
Journal Articles

Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström macroglobulinemia

Clinical Trials & Observations
Sabrin Tahri, Tarek H. Mouhieddine, Robert Redd, Luisa Lampe, Katarina I. Nilsson, Habib El-Khoury, Nang Kham Su, Amin H. Nassar, Elio Adib, Govind Bindra, Sarah Abou Alaiwi, Lorenzo Trippa, David P. Steensma, Jorge J. Castillo, Steven P. Treon, Irene M. Ghobrial, Adam S. Sperling
Journal: Blood Advances
Blood Adv (2022) 6 (7): 2230–2235.
https://doi.org/10.1182/bloodadvances.2021004926
Published: 2022
Includes: Supplemental data
Journal Articles

Guideline-based indicators for adult patients with myelodysplastic syndromes

Kristina Stojkov, Tobias Silzle, Georg Stussi, David Schwappach, Juerg Bernhard, David Bowen, Jaroslav Čermák, Avinash G. Dinmohamed, Corien Eeltink, Sabrina Eggmann, Pierre Fenaux, Ulrich Germing, Manuel Haschke, Eva Hellstrom-Lindberg, Monika Heger, Arjan A. van de Loosdrecht, Jakob Passweg, Michael Pfeilstöcker, Uwe Platzbecker, Luca Malcovati, António Medina de Almeida, Moshe Mittelman, Christine Morgenthaler, David P. Steensma, Valeria Santini, Reinhard Stauder, Argiris Symeonidis, Sämi Schär, Charlotte Maddox, Theo de Witte, Julia Bohlius, Nicolas Bonadies
Journal: Blood Advances
Blood Adv (2020) 4 (16): 4029–4044.
https://doi.org/10.1182/bloodadvances.2020002314
Published: 2020
Includes: Supplemental data
Journal Articles

Clinicopathologic and genetic characterization of nonacute NPM1 -mutated myeloid neoplasms

Clinical Trials & Observations
Sanjay S. Patel, Caleb Ho, Ryan N. Ptashkin, Sam Sadigh, Adam Bagg, Julia T. Geyer, Mina L. Xu, Thomas Prebet, Emily F. Mason, Adam C. Seegmiller, Elizabeth A. Morgan, David P. Steensma, Eric S. Winer, Waihay J. Wong, Robert P. Hasserjian, Olga K. Weinberg
Journal: Blood Advances
Blood Adv (2019) 3 (9): 1540–1545.
https://doi.org/10.1182/bloodadvances.2019000090
Published: 2019
Journal Articles

Clinical consequences of clonal hematopoiesis of indeterminate potential

David P. Steensma
Journal: Blood Advances
Blood Adv (2018) 2 (22): 3404–3410.
https://doi.org/10.1182/bloodadvances.2018020222
Published: 2018
Journal Articles

The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort

Clinical Trials & Observations
Maximilian Stahl, Michelle DeVeaux, Theo de Witte, Judith Neukirchen, Mikkael A. Sekeres, Andrew M. Brunner, Gail J. Roboz, David P. Steensma, Vijaya R. Bhatt, Uwe Platzbecker, Thomas Cluzeau, Pedro H. Prata, Raphaël Itzykson, Pierre Fenaux, Amir T. Fathi, Alexandra Smith, Ulrich Germing, Ellen K. Ritchie, Vivek Verma, Aziz Nazha, Jaroslaw P. Maciejewski, Nikolai A. Podoltsev, Thomas Prebet, Valeria Santini, Steven D. Gore, Rami S. Komrokji, Amer M. Zeidan
Journal: Blood Advances
Blood Adv (2018) 2 (14): 1765–1772.
https://doi.org/10.1182/bloodadvances.2018019414
Published: 2018
Journal Articles

Risk and timing of cardiovascular death among patients with myelodysplastic syndromes

Clinical Trials & Observations
Andrew M. Brunner, Traci M. Blonquist, Gabriela S. Hobbs, Philip C. Amrein, Donna S. Neuberg, David P. Steensma, Gregory A. Abel, Amir T. Fathi
Journal: Blood Advances
Blood Adv (2017) 1 (23): 2032–2040.
https://doi.org/10.1182/bloodadvances.2017010165
Published: 2017
Includes: Supplemental data
Journal Articles

Systematic STAT3 sequencing in patients with unexplained cytopenias identifies unsuspected large granular lymphocytic leukemia

Elizabeth A. Morgan, Mark N. Lee, Daniel J. DeAngelo, David P. Steensma, Richard M. Stone, Frank C. Kuo, Jon C. Aster, Christopher J. Gibson, R. Coleman Lindsley
Journal: Blood Advances
Blood Adv (2017) 1 (21): 1786–1789.
https://doi.org/10.1182/bloodadvances.2017011197
Published: 2017
Includes: Supplemental data